Moreover, it was shown that, in a breast cancer mouse model, tranilast treatment upregulates p53 and induces PARP and CASP3 cleavage in in vitro, consistent with the promotion of tumor cell apoptosis (Subramaniam et al., 2010). Here, TP53 is linked to breast cancer.